SCHEMBL479127

SCHEMBL479127

CCOC(C[SiH3])(OCC)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 4/20 0.38
MAPK1 P28482 1/20 0.37
KIF11 P52732 2/20 0.35
TAAR1 Q96RJ0 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX15 P16050 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
LTA4H P09960 1/20 0.32
EDNRB P24530 1/20 0.32
EDNRA P25101 1/20 0.32
CYP2C19 P33261 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5962153 0.83 KCNN4 (0.40) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL7606440 0.79 KCNN4 (0.38) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL3891423 0.79 KCNN4 (0.38) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL4058230 0.79 TAAR1 (0.48) KCNN4MAPK1KIF11TAAR1
SCHEMBL16144806 0.78 KCNN4 (0.42) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL3663149 0.78 CYP1A2 (0.45) KCNN4KIF11TAAR1ALDH1A1CYP3A4
SCHEMBL28893285 0.78 MAPK1 (0.40) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL3933085 0.78 KCNN4 (0.38) KCNN4MAPK1KIF11TAAR1ALDH1A1
SCHEMBL6755985 0.75 LTA4H (0.37) KCNN4KIF11CYP3A4CYP2D6CHRM2
SCHEMBL27665132 0.75 CYP2C19 (0.53) KCNN4ALDH1A1CYP3A4CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216952-B2 Process for preparing antiviral compound ABBVIE INC. (US) 2015-12-22 US claimed
US-9181399-B2 Method for producing polysiloxane TOAGOSEI CO., LTD. (JP) 2015-11-10 US claimed
US-20140303392-A1 METHOD FOR PRODUCING POLYSILOXANE TOAGOSEI CO., LTD. (JP) 2014-10-09 US claimed
EP-2411372-B1 PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND ABBVIE BAHAMAS LTD (BS) 2014-07-23 EP claimed
EP-2411372-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND Abbott Laboratories (US) 2012-02-01 EP claimed
US-20110237793-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ABBOTT LABORATORIES (US) 2011-09-29 US claimed
WO-2010111348-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ABBOTT LABORATORIES (US) 2010-09-30 WO claimed
US-20240158904-A1 UNDERCOAT AGENT COMPOSITION FOR LAYERING INORGANIC MATERIAL LAYER, CURED PRODUCT THEREOF AND PRODUCTION METHOD THEREOF TOAGOSEI CO., LTD. (JP) 2024-05-16 US disclosed
US-11981828-B2 Water repellent and oil repellent film composition and use thereof TOAGOSEI CO. LTD. (JP) 2024-05-14 US disclosed
CN-115103872-B Silsesquioxane derivative and use thereof 东亚合成株式会社 2024-02-02 CN disclosed
EP-4289618-A1 UNDERCOAT AGENT COMPOSITION FOR INORGANIC SUBSTANCE LAYER LAMINATION, CURED PRODUCT THEREOF, AND METHOD FOR PRODUCING SAME Toagosei Co., Ltd. (JP) 2023-12-13 EP disclosed
CN-112888715-B Silsesquioxane derivative composition and use thereof 东亚合成株式会社 2023-11-03 CN disclosed
CN-116897195-A Primer composition for inorganic substance layer lamination, cured product thereof, and method for producing same 东亚合成株式会社 2023-10-17 CN disclosed
US-9216952-B2 Process for preparing antiviral compound ABBVIE INC. (US) 2015-12-22 US disclosed
US-9181399-B2 Method for producing polysiloxane TOAGOSEI CO., LTD. (JP) 2015-11-10 US disclosed
US-20140303392-A1 METHOD FOR PRODUCING POLYSILOXANE TOAGOSEI CO., LTD. (JP) 2014-10-09 US disclosed
EP-2411372-B1 PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND ABBVIE BAHAMAS LTD (BS) 2014-07-23 EP disclosed
EP-2411372-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND Abbott Laboratories (US) 2012-02-01 EP disclosed
US-20110237793-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ABBOTT LABORATORIES (US) 2011-09-29 US disclosed
WO-2010111348-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ABBOTT LABORATORIES (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237793-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ZC3HAV1, HAVCR2, MAVS KCNN4 4562/4885MAPK1 2356/4885KIF11 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.